Short answer
FATE THERAPEUTICS INC (FATE) filed an 8-K current report with the SEC on September 28, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). CIRM awarded Fate Therapeutics a $15 million grant on September 25, 2026.
FATE THERAPEUTICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- CIRM awarded Fate Therapeutics a $15 million grant on September 25, 2026
- Funding supports Phase 2 RECLAIM-LN clinical trial of FT819
- Non-dilutive financing reduces potential capital needs for FT819 development
- Press release filed as Exhibit 99.1 contains additional program details
Item EX-99.1 · Exhibit EX-99.1
- $15.0M CIRM CLIN2 grant supports RECLAIM-LN, reducing Fate’s funding burden for FT819’s lupus nephritis development
- RECLAIM-LN is a Phase 2 potentially registrational trial targeting approximately 53 refractory patients
- Primary endpoint: complete renal response at Week 26, making trial data potentially pivotal for regulatory strategy
- FT819’s off-the-shelf model could expand CAR T access beyond specialized centers, supporting broader commercial potential
- Key risks remain clinical efficacy, patient enrollment, manufacturing, and regulatory approval despite RMAT and CDRP participation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other FATE THERAPEUTICS INC 8-K filings
Get the next FATE 8-K as it lands
Follow FATE for push alerts, or ask the research agent what this filing means.